Tap Into a Global Network of Established & Emerging Stakeholders in Pain R&D
Following the first approval of a NaV1.8 therapy, the non-opioid pain landscape has rapidly become one of biopharma's most active areas for investment, partnering, and innovation. High-profile transactions, including Eli Lilly's $1 billion acquisition of SiteOne Therapeutics and 4E Therapeutics, AbbVie's $745 million licensing agreement with Haisco, and Medtronic's acquisition of SPR Therapeutics, highlight growing industry confidence across sodium channel biology, novel molecular mechanisms, and next-generation pain treatment modalities.
As developers advance NaV1.8, V1.7, and 1.9 inhibitors, Ca2+ and KV+ channel modulators, neurotrophin-targeted therapies, GLP-1 approaches, gene regulation technologies, and other emerging mechanisms, demand for specialist expertise has never been greater, and with 1.5 billion individuals globally living with chronic pain, it’s no shock the pain management market will hit $96 billion in 2030. The 2nd Non-Opioid Pain Therapeutics Summit will unite 150+ senior leaders from biotech, pharma, academia, and investment, including decision-makers from Vertex Pharmaceuticals, Eli Lilly, AbbVie, Grünenthal, Xenon Pharmaceuticals, Merck, Novo Holdings, Tris Pharma, Latigo Biotherapeutics, SimR Biosciences, Maxona Pharmaceuticals, and more, creating a unique platform to showcase your capabilities, build strategic partnerships and position your organization at the forefront of this rapidly evolving field.
Are you looking to connect with the companies advancing the next generation of non-opioid pain therapies and position your organization as a trusted partner in one of biopharma's fastest-growing markets?
Focused community of experts, great networking, quality of the speakers and the talks, size and duration of the event (great for networking)
Global Pain SME & Business Development Professional - Transpharmation
Excellent group of speakers, really appreciated the panel discussions
Chief Scientific Officer - Nocion Therapeutics, Inc.
The quality of people and content
VP Business Development - MD Biosciences
Very high-quality speakers and attendees
Chief Executive Officer - Brooklyn Clinical Research
Great lectures and opportunities to meet with industry colleagues. Transparently, I came to connect with as many pharma companies as I could. The format was extremely strong…
Chief Medical Officer - Conquest Research
Many people, great talks and plenty of networking opportunities
GM - Metrion Biosciences
Good spectrum of attendees, including industry folks, and valuable presentations. Good environment to have discussions
House Counsil - Lohocla Research Corp.
Networking sessions, including lunch, the reception and the workshops were all excellent.
Consultant - KapNeuro Consulting
The presence of new players and a platform for discussion
Consultant - RCG Intel
There was a good mix of talks from the preclinical level to clinical stage and an excellent workshop with Bruce Bean and Clifford Woolf. The panel with the search and evaluation directors from large pharma was helpful
VP, Business Development - AnaBios Corporation
What To Expect
P | Power New Partnerships - Connect with decision-makers driving the next generation of pain therapeutics.
A | Advance Your Knowledge - Learn from experts across discovery, clinical development and commercialization.
I | Influence the Conversation - Share insights and elevate your visibility within the pain community.
N | Network with Purpose - Forge meaningful relationships that accelerate business and scientific goals.
Key Services & Solutions
What Types of Companies Can Benefit Most from a Partnership with the 2nd Non-Opioid Pain Therapeutics Summit?
- Human-Relevant Pain Models
Advanced iPSC-derived sensory neurons, human DRG platforms, organoids, and translational assays to improve clinical predictability beyond traditional animal models. - Preclinical CROs & Pain Pharmacology Services
Specialist partners offering in vitro and in vivo pain models, efficacy studies, translational pharmacology, and IND-enabling support for non-opioid pain programs. - Ion Channel Assays & Electrophysiology Platforms
Automated patch clamp, target validation, and screening technologies are accelerating discovery across NaV, Kv7, CaV, and other emerging pain targets. - Biomarker & Target Engagement Technologies
Microneurography, imaging, molecular biomarkers, and quantitative tools to demonstrate mechanism engagement, support dose selection, and improve clinical translation. - Clinical CROs & Trial Design Expertise
Support with placebo mitigation, patient stratification, endpoint development, site selection, and execution of acute, neuropathic, and chronic pain studies.
Audience Composition
Seniority of Attendees
Types of Companies Attending
Attending Companies Include
Available Inventory
We have a range of inventory from standard booth and speaking slots to more bespoke deliverables such as lanyards, exclusive dinners and tours to help elevate your brand.
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us at sponsor@hansonwade.com if you would like to get involved and discuss a bespoke package suited to your needs.
Jessica Alarms
Partnerships Director
Maintain Your Competitive Edge
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma discussions.
Network With Decision-Makers
Speak with our audience of senior scientific experts during dedicated meeting breaks and structured networking opportunities.
Showcase Your Capabilities
Explore our bespoke sponsorship options including branding, presenting, and exhibiting to build a package tailored to you and your company's goals.